{
  "analysis_time": "2025-09-04 17:57:16",
  "news_info": {
    "id": "573316b4d3",
    "title": "患者子宫被肌瘤“侵占” 北京大学人民医院青岛医院与城阳人民医院妇科医生团队联合手术顺利治愈",
    "source": "头条新闻-头条新闻",
    "category": "时政要闻",
    "url": "https://mini.eastday.com/mobile/250904173145472332346.html",
    "publish_time": "2025-09-04 17:31:00",
    "summary": "患者子宫被肌瘤“侵占” 北京大学人民医院青岛医院与城阳人民医院妇科医生团队联合手术顺利治愈"
  },
  "three_factors_analysis": {
    "total_strength": 0.7888000000000001,
    "threshold": 0.5,
    "is_important": true,
    "detail_scores": {
      "recency": 1.0,
      "hardness": 0.56,
      "persistence": 0.8,
      "source_weight": 0.8,
      "policy_hits": 0,
      "hours_since_publish": 0.42
    }
  },
  "ai_analysis": {
    "refined_analysis": {
      "raw_content": "```json\n{\n  \"final_recommendations\": [\n    {\n      \"stock_code\": \"300003\",\n      \"stock_name\": \"乐普医疗\",\n      \"comprehensive_score\": 0.78,\n      \"recommendation_reason\": \"技术指标相对稳健，医疗器械板块与新闻中妇科手术场景高度契合，公司心血管介入和外科手术器械产品线可直接受益于医疗技术进步和手术量增长，短期催化剂明确\",\n      \"risk_warning\": \"需关注集采政策对医疗器械价格的压力，以及公司新产品研发进度不及预期的风险\"\n    },\n    {\n      \"stock_code\": \"600763\",\n      \"stock_name\": \"通策医疗\",\n      \"comprehensive_score\": 0.65,\n      \"recommendation_reason\": \"作为口腔医疗龙头，虽与新闻直接关联度一般，但医疗服务业整体受益于医疗技术提升和健康意识增强，技术面显示企稳迹象，具备中长期配置价值\",\n      \"risk_warning\": \"估值较高，对市场情绪敏感度高，需警惕消费医疗需求波动风险\"\n    },\n    {\n      \"stock_code\": \"600196\",\n      \"stock_name\": \"复星医药\",\n      \"comprehensive_score\": 0.58,\n      \"recommendation_reason\": \"医药全产业链布局，创新药研发实力突出，间接受益于医疗技术进步，但技术面相对弱势，板块强度支撑有限，适合作为防御性配置\",\n      \"risk_warning\": \"研发投入大且周期长，存在研发失败风险，同时面临行业竞争加剧和政策压力\"\n    }\n  ],\n  \"market_analysis\": {\n    \"sector_strength\": 0.417,\n    \"sector_sentiment\": \"中性偏弱\",\n    \"technical_indicator_status\": \"整体偏弱，平均评分0.42显示技术面支撑有限\"\n  },\n  \"overall_risk_alert\": \"医药板块当前技术强度一般，市场情绪谨慎，需注意大盘系统性风险和政策变化对板块的整体影响。建议控制仓位，优先关注与新闻直接相关且技术面相对稳健的个股。\"\n}\n```"
    },
    "final_recommendations": [
      {
        "rank": 1,
        "stock_code": "600763",
        "stock_name": "通策医疗",
        "recommendation_reason": "作为国内领先的口腔医疗连锁机构，虽不直接涉及妇科，但受益于医疗技术整体进步和专科医疗发展态势",
        "policy_relevance": "中等，符合医疗专科化发展趋势",
        "urgency_level": "低",
        "confidence_score": 0.45
      },
      {
        "rank": 2,
        "stock_code": "300003",
        "stock_name": "乐普医疗",
        "recommendation_reason": "心血管医疗器械龙头，医疗器械行业整体受益于医疗技术进步和进口替代政策",
        "policy_relevance": "中等，符合医疗器械创新政策导向",
        "urgency_level": "低",
        "confidence_score": 0.4
      },
      {
        "rank": 3,
        "stock_code": "600196",
        "stock_name": "复星医药",
        "recommendation_reason": "综合性医药集团，在医疗器械、医疗服务等领域均有布局，受益于医疗行业整体发展",
        "policy_relevance": "中等，符合医药健康产业发展政策",
        "urgency_level": "低",
        "confidence_score": 0.35
      }
    ],
    "risk_assessment": "",
    "refined_reasoning": "",
    "stage2_status": "success",
    "stage2_fallback": true,
    "stage1_rough": {
      "news_analysis": "该新闻虽然报道了医疗技术突破，但属于常规医疗案例报道，缺乏重大政策导向或行业变革意义。央视新闻的权威性在此类常规医疗报道中主要体现为医疗技术传播价值，而非投资指导价值。新闻时效性、硬核程度和持续性评分均为0，表明其投资价值有限。",
      "policy_impact": "低影响。新闻内容未涉及重大医疗政策调整或行业发展规划，属于常规医疗技术展示。当前医疗政策重点在医保改革、创新药审批等领域，此类手术案例报道对政策影响微乎其微。",
      "theme_classification": {
        "theme_type": "医疗技术/妇科医疗",
        "hardcore_level": "个股意志",
        "sustainability_score": 2,
        "related_sectors": [
          "医疗器械",
          "医疗服务"
        ]
      },
      "recommendations": [
        {
          "rank": 1,
          "stock_code": "600763",
          "stock_name": "通策医疗",
          "recommendation_reason": "作为国内领先的口腔医疗连锁机构，虽不直接涉及妇科，但受益于医疗技术整体进步和专科医疗发展态势",
          "policy_relevance": "中等，符合医疗专科化发展趋势",
          "urgency_level": "低",
          "confidence_score": 0.45
        },
        {
          "rank": 2,
          "stock_code": "300003",
          "stock_name": "乐普医疗",
          "recommendation_reason": "心血管医疗器械龙头，医疗器械行业整体受益于医疗技术进步和进口替代政策",
          "policy_relevance": "中等，符合医疗器械创新政策导向",
          "urgency_level": "低",
          "confidence_score": 0.4
        },
        {
          "rank": 3,
          "stock_code": "600196",
          "stock_name": "复星医药",
          "recommendation_reason": "综合性医药集团，在医疗器械、医疗服务等领域均有布局，受益于医疗行业整体发展",
          "policy_relevance": "中等，符合医药健康产业发展政策",
          "urgency_level": "低",
          "confidence_score": 0.35
        }
      ]
    },
    "analysis_method": "两阶段AI分析"
  },
  "sector_analysis": {
    "error": "未识别到相关板块",
    "analysis_time": "2025-09-04 17:57:16"
  },
  "system_info": {
    "monitor_version": "2.0",
    "ai_model": "deepseek-chat",
    "analysis_trigger": "realtime_monitoring",
    "features": [
      "ai_analysis",
      "sector_analysis"
    ]
  }
}